Canada markets closed

Agile Therapeutics, Inc. (AGRX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3700+0.0023 (+0.61%)
At close: 03:56PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 2.54M
Enterprise Value 2.15M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)0.04
Price/Book (mrq)1.78
Enterprise Value/Revenue 0.11
Enterprise Value/EBITDA -0.17

Trading Information

Stock Price History

Beta (5Y Monthly) 1.40
52-Week Change 3-94.45%
S&P500 52-Week Change 321.23%
52 Week High 37.0000
52 Week Low 30.2000
50-Day Moving Average 30.6810
200-Day Moving Average 31.7633

Share Statistics

Avg Vol (3 month) 3730.58k
Avg Vol (10 day) 3128.12k
Shares Outstanding 56.86M
Implied Shares Outstanding 67.91M
Float 86.85M
% Held by Insiders 10.42%
% Held by Institutions 13.71%
Shares Short (Feb 29, 2024) 4222.1k
Short Ratio (Feb 29, 2024) 40.28
Short % of Float (Feb 29, 2024) 47.50%
Short % of Shares Outstanding (Feb 29, 2024) 47.49%
Shares Short (prior month Jan 31, 2024) 4189.89k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:50
Last Split Date 3Apr 11, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin -73.83%
Operating Margin (ttm)-112.12%

Management Effectiveness

Return on Assets (ttm)-101.46%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)19.59M
Revenue Per Share (ttm)9.09
Quarterly Revenue Growth (yoy)-9.60%
Gross Profit (ttm)N/A
EBITDA -19.5M
Net Income Avi to Common (ttm)-14.46M
Diluted EPS (ttm)-6.7100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.56M
Total Cash Per Share (mrq)0.37
Total Debt (mrq)2.17M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.46
Book Value Per Share (mrq)-5.51

Cash Flow Statement

Operating Cash Flow (ttm)-9.58M
Levered Free Cash Flow (ttm)-3.68M